SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis

Is the use of sodium-glucose cotransporter–2 inhibitors (SGLT2is) associated with improved cardiorenal and hepatic outcomes in patients with type 2 diabetes (T2D) and liver cirrhosis?In this cohort study of 24 259 patients with T2D and cirrhosis, SGLT2is were associated with decreased risk of end-stage kidney disease, acute kidney injury, major adverse cardiovascular events, and all-cause mortality during a median follow-up of 2.3 years. SGLT2is were also associated with reduced risk of hepatic decompensation events, with consistent results across sensitivity and subgroup analyses.These findings suggest that SGLT2is may provide significant cardiorenal and hepatic protection for patients with coexisting T2D and liver cirrhosis.

Corresponding Author: Chi-Jung Chung, PhD, Department of Public Health, College of Public Health, China Medical University, No. 100, Sec. 1, Jingmao Rd, Beitun Dist, Taichung City 406040, Taiwan (cjchung@mail.cmu.edu.tw).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.